No differences in calcium-binding protein immunoreactivity in the posterior cingulate and visual cortex: schizophrenia and controls

Progress in Neuro-psychopharmacology & Biological Psychiatry
David G WheelerClive Harper

Abstract

Schizophrenia-specific alterations in the densities of interneurons immunoreactive (ir) to the calcium binding proteins are reported for several cortical regions. However, no reported studies have searched for such differences within the posterior cingulate cortex using antibodies to a specific calcium binding protein, calbindin (Cb). Compare the (a) relative density of Cb-ir neurons (ratio of labeled neurons to total neurons), (b) relative width of cortical layers II/III and (c) somal areas of Cb-ir neurons in people with schizophrenia and non-psychiatric age-, gender- and postmortem index-matched controls (9 per group). Tissue from Brodmann's area (BA) 30 and 23 and an internal control region, the visual cortex (BA 18) were labeled with polyclonal Cb antibodies then Nissl counter-stained. Cb-ir neurons as well as counter-stained neurons with clearly visible nucleoli were plotted and counted within their area 1 and laminar boundaries. No qualitative or statistical differences in the relative density of Cb-ir neurons were observed. A trend towards a significant effect was detected in BA 30, the relative density of Cb-ir neurons for controls was greater than for schizophrenics (P=0.0518). There were no significant differences in...Continue Reading

References

Jul 1, 1988·Journal of Microscopy·H J Gundersen
Jul 1, 1987·The American Journal of Psychiatry·R S KeefeK L Davis
Apr 1, 1981·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·S M HsuH Fanger
Aug 28, 1995·The Journal of Comparative Neurology·B A VogtP R Hof
May 1, 1995·The American Journal of Psychiatry·S E ArnoldJ Q Trojanowski
Jan 1, 1994·Journal of Neuroscience Methods·A J HardingK Cullen
Mar 1, 1993·The American Journal of Psychiatry·C N KarsonW S Griffin
Apr 1, 1996·The American Journal of Psychiatry·C HillD Copolov
Feb 1, 1997·Psychiatry and Clinical Neurosciences·T OhnumaH Arai
Apr 11, 1997·Schizophrenia Research·C L Beasley, G P Reynolds
Apr 1, 1997·Brain : a Journal of Neurology·V B Mountcastle
Aug 11, 1997·The Journal of Comparative Neurology·E A NimchinskyP R Hof
Sep 3, 1999·Biological Psychiatry·S V KyossevaC N Karson
Mar 17, 2000·Brain Research. Brain Research Reviews·F M Benes
May 17, 2000·The Journal of Comparative Neurology·R MorrisM Petrides
Jul 27, 2001·Journal of Chemical Neuroanatomy·G P Reynolds, C L Beasley
Aug 8, 2002·Schizophrenia Research·D W EylesG P Reynolds
Jan 7, 2004·Molecular Psychiatry·Michael B KnableUNKNOWN Stanley Neuropathology Consortium
Jan 31, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·Paul A Tooney, Loris A Chahl
Nov 25, 2004·Schizophrenia Research·Serge A MitelmanMonte S Buchsbaum

❮ Previous
Next ❯

Citations

Apr 1, 2009·International Journal of Molecular Sciences·Irina DedovaClive G Harper
Apr 28, 2007·The Australian and New Zealand Journal of Psychiatry·Daren M DraganicVaughan J Carr
Dec 7, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Cheng Z WangKenneth M Johnson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here